Gemini Therapeutics (GMTX) Competitors

Qiagen (NYSE:QGEN) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Is QGEN or GMTX more profitable?

Qiagen has a net margin of 4.23% compared to Gemini Therapeutics' net margin of 0.00%. Qiagen's return on equity of 13.92% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	4.23%	13.92%	8.40%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Does the media refer more to QGEN or GMTX?

In the previous week, Qiagen had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Qiagen and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 1.11 beat Qiagen's score of 0.26 indicating that Gemini Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gemini Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in QGEN or GMTX?

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts recommend QGEN or GMTX?

Qiagen currently has a consensus price target of $47.71, suggesting a potential upside of 20.32%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Qiagen is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community believe in QGEN or GMTX?

Qiagen received 230 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. However, 63.33% of users gave Gemini Therapeutics an outperform vote while only 60.29% of users gave Qiagen an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 249 60.29%	Underperform Votes 164 39.71%
Gemini Therapeutics	Outperform Votes 19 63.33%	Underperform Votes 11 36.67%

Which has more risk & volatility, QGEN or GMTX?

Qiagen has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.

Which has preferable earnings & valuation, QGEN or GMTX?

Qiagen has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.98B	4.45	$83.59M	$0.36	110.14
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	-52.49

Summary

Qiagen beats Gemini Therapeutics on 13 of the 17 factors compared between the two stocks.